Jason Mouabbi, Assistant Professor at MD Anderson Cancer Center, shared on LinkedIn:
“Fantastic news to end the week!
FDA accelerated approval: camizestrant + CDK4/6i at ESR1 emergence on 1L AI + CDK4/6i (SERENA-6). mPFS 16.0 vs 9.2 mo, HR 0.44.
First approval ever driven by ctDNA, not imaging. Molecular progression is now actionable in the US.
So happy for our patients who want to stay a step ahead of their cancer.”
You can also read:
FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Advanced Breast Cancer
